In Silico Biosciences

Central Nervous System (CNS) Modeling & Drug Discovery Support

The vision of In Silico Biosciences is that one day, through a quantum leap in understanding diseases of the central nervous system, we have developed breakthrough drugs that have cured diseases of the brain, including Alzheimer’s, Parkinson’s, and Schizophrenia.

Our Vision

At In Silico Biosciences, Inc. we aim to use decades worth of collected clinical and biomedical data to guide the development of biophysically realistic model systems to better understand disease processes in the nervous system and their optimized treatment in patients.

We envision that our approach will guide breakthrough developments for intractable nervous system diseases, and modernize drug discovery in the 21st century by integrating big data into model-based predictions.

Our dedicated staff make better use of human intellectual capital by employing highly sophisticated modern computer-based modeling to predict patient responses to particular therapies.

ISB is at the forefront of a new form of quantitative systems pharmacology (QSP). QSP is a powerful convergence of biological pathways and pharmacology. ISB employs its patented mathematical modeling approaches to facilitate discovery of new therapeutics and enable individualized medicine for effective and safe treatments with existing drugs.

Services

We offer computer simulation support in drug development, based on the affinity and pharmacology of a new drug towards human receptors for Alzheimer’s disease, Schizophrenia, and Parkinson’s disease.

  • Preclinical Discovery
    • Validating the impact of targets in the combined neuronal circuit outcome
    • Candidate selection in multi-target medicinal chemistry campaign
    • Off-target pharmacological activity of candidate compounds
    • Early assessment of human metabolite effects of candidate compounds
    • Synergistic effects of off-target pharmacological activity of candidate compounds
  • Early Clinical Development
    • Prediction of functional biomarkers (pharmaco-fMRI, pharmaco-EEG)
    • Optimal dosage and dosage schedule
  • Late Clinical Development
    • Simulations of comedication effects on primary pharmacology
    • Effect of genotype randomization
    • Virtual patient trial based on pharmacokinetic and mechanistic pharmacodynamic simulation
    • Chronopharmacology, i.e. optimal dosing time given the circadian rhythm of specific brain circuits
  • Post-Marketing
    • Simulation of different switching schedules
    • Understanding the biology behind pharmacogenomics analysis of responders
    • Optimization of clinical head-to-head trials
    • Simulations of the drug in real-life conditions (i.e. polypharmacy)

Technology

The ISB Platform is State-of-the-Art in CNS Quantitative Systems Pharmacology

ISB’s top-down computer simulation of complex CNS pathological processes in psychiatric and neurological disorders, based upon signal processing between different brain regions, is a new form of quantitative systems pharmacology.

How ISB Builds Biophysically Realistic Human CNS Disease Models

We make our computational neuroscience expertise actionable for CNS Research and Development by introducing human pathology, neuromodulatory physiology, and the pharmacology of CNS active compounds to predict the alteration of neuron activity through targeted delivery of a stimulus, such as chemical agents (drugs) to specific neurological sites in the human body

Interested in Learning More?

Clinicians interested in learning more about ISB’s modeling capabilities can submit an inquiry here. Your contact information will not be shared and will only be used by ISB to keep you updated about our services.

RECENT PUBLICATIONS
CASE STUDIES
In Silico Biosciences
Inspiring Discovery | Guiding Results
Linkedin University

Our Work

About

News & Events